Compounds > moli1901
Page last updated: 2024-10-15

moli1901

Description

Moli1901: a 19 amino acid polycyclic peptide; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID139593411
MeSH IDM0453728

Synonyms (12)

Synonym
antibiotic pa 48009
leucopeptin
ancovenin, 2-l-lysine-6-(3-aminoalanine)-10-l-phenylalanine-12-l-phenylalanine-13-l-valine-15-(erythro-3-hydroxy-l-aspartic acid)-, cyclic 6-19)-imine
moli1901
bpr0f3x56h ,
lancovutide [inn]
moli 1901
unii-bpr0f3x56h
moli-1901
ancovenin, 2-l-lysine-6-(3-aminoalanine)-10-l-phenylalanine-12-l-phenylalanine-13-l-valine-15-(erythro-3-hydroxy-l-aspartic acid)-, cyclic (6->19)-imine
lancovutide [who-dd]
l-lysine, l-cysteinyl-l-lysyl-l-glutaminyl-d-cysteinyl-l-cysteinyl-3-aminoalanyl-l-phenylalanylglycyl-l-prolyl-l-phenylalanyl-(2s,3s)-2-amino-3-mercaptobutanoyl-l-phenylalanyl-l-valyl-l-cysteinyl-(3r)-3-hydroxy-l-.alpha.-aspartylglycyl-l-asparaginyl-(2s,3

Research Excerpts

Overview

Moli1901 is a 19 residue polycyclic peptide antibiotic. Increases chloride transport and water mobilization in airway epithelium.

ExcerptReference
"Moli1901 is a 19 residue polycyclic peptide antibiotic which increases chloride transport and water mobilization in airway epithelium. "( Determination of the tissue distribution and excretion by accelerator mass spectrometry of the nonadecapeptide 14C-Moli1901 in beagle dogs after intratracheal instillation.
Dingley, K; Dix, KJ; Molina, L; Rickert, DE; Ubick, E, 2005)

Dosage Studied

ExcerptReference
" A dose-response relationship to Moli1901 was observed in non-CF participants, but a greater range of variability within the CF participants contributed to the lack of a clear dose-response relationship in this group."( A phase I trial of intranasal Moli1901 for cystic fibrosis.
Boyle, MP; Guggino, WB; Molina, L; Zeitlin, PL, 2004)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's0 (0.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (50.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2 (33.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
isoproterenol
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.		4.3211catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
uridine
[no description available]		3.1410uridinesdrug metabolite;
fundamental metabolite;
human metabolite
mannitol
[no description available]		3.1410mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
amiloride
Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.		4.3211aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
denufosol tetrasodium
denufosol tetrasodium: for treatment of cystic fibrosis		3.1410
ConditionIndicatedRelationship StrengthStudiesTrials
Cystic Fibrosis of Pancreas
[description not available]		09.8586
Cystic Fibrosis
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.		09.8586